Hims & Hers Health, Inc. (NYSE:HIMS) CEO Andrew Dudum Sells 36,460 Shares

Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) CEO Andrew Dudum sold 36,460 shares of the business's stock in a transaction on Wednesday, April 16th. The stock was sold at an average price of $28.04, for a total value of $1,022,338.40. Following the transaction, the chief executive officer now directly owns 92,103 shares of the company's stock, valued at $2,582,568.12. This trade represents a 28.36 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Andrew Dudum also recently made the following trade(s):

• On Monday, March 17th, Andrew Dudum sold 128,127 shares of Hims & Hers Health stock. The shares were sold at an average price of $33.98, for a total transaction of $4,353,755.46.
• On Tuesday, February 18th, Andrew Dudum sold 128,127 shares of Hims & Hers Health stock. The shares were sold at an average price of $58.27, for a total transaction of $7,465,960.29.
• On Friday, January 31st, Andrew Dudum sold 100,000 shares of Hims & Hers Health stock. The stock was sold at an average price of $35.22, for a total transaction of $3,522,000.00.
• On Thursday, January 23rd, Andrew Dudum sold 27,098 shares of Hims & Hers Health stock. The stock was sold at an average price of $30.08, for a total transaction of $815,107.84.
• On Tuesday, January 21st, Andrew Dudum sold 300 shares of Hims & Hers Health stock. The stock was sold at an average price of $30.00, for a total value of $9,000.00.

Hims & Hers Health Stock Up 5.5 %

NYSE HIMS traded up $1.40 during trading hours on Wednesday, reaching $26.75. 22,002,418 shares of the company were exchanged, compared to its average volume of 15,511,635. The stock has a market capitalization of $5.94 billion, a P/E ratio of 60.80 and a beta of 1.65. Hims & Hers Health, Inc. has a 1 year low of $11.20 and a 1 year high of $72.98. The business's 50 day simple moving average is $35.50 and its 200-day simple moving average is $30.78.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last announced its quarterly earnings data on Monday, February 24th. The company reported $0.11 earnings per share for the quarter, beating the consensus estimate of $0.09 by $0.02. The business had revenue of $481.14 million during the quarter, compared to analyst estimates of $494.56 million. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. As a group, sell-side analysts anticipate that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on the company. Morgan Stanley lowered Hims & Hers Health from an "overweight" rating to an "equal weight" rating and lifted their price target for the company from $42.00 to $60.00 in a research note on Tuesday, February 18th. Canaccord Genuity Group raised their price target on shares of Hims & Hers Health from $38.00 to $68.00 and gave the company a "buy" rating in a research note on Wednesday, February 19th. Truist Financial reduced their price objective on shares of Hims & Hers Health from $39.00 to $33.00 and set a "hold" rating on the stock in a research note on Thursday, April 10th. Bank of America lifted their target price on Hims & Hers Health from $21.00 to $22.00 and gave the stock an "underperform" rating in a report on Tuesday, March 18th. Finally, Leerink Partners increased their price target on Hims & Hers Health from $24.00 to $40.00 and gave the company a "market perform" rating in a research note on Tuesday, February 25th. Two equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and five have assigned a buy rating to the company's stock. According to MarketBeat, Hims & Hers Health currently has an average rating of "Hold" and a consensus target price of $38.25.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. grew its position in shares of Hims & Hers Health by 11.1% in the fourth quarter. Vanguard Group Inc. now owns 20,257,116 shares of the company's stock valued at $489,817,000 after purchasing an additional 2,020,722 shares in the last quarter. Farallon Capital Management LLC increased its position in shares of Hims & Hers Health by 64,338.5% during the fourth quarter. Farallon Capital Management LLC now owns 8,377,000 shares of the company's stock valued at $202,556,000 after buying an additional 8,364,000 shares during the period. Renaissance Technologies LLC lifted its holdings in shares of Hims & Hers Health by 29.0% in the fourth quarter. Renaissance Technologies LLC now owns 6,951,152 shares of the company's stock worth $168,079,000 after buying an additional 1,562,302 shares in the last quarter. Arrowstreet Capital Limited Partnership boosted its position in shares of Hims & Hers Health by 192.0% in the fourth quarter. Arrowstreet Capital Limited Partnership now owns 6,304,202 shares of the company's stock valued at $152,436,000 after acquiring an additional 4,145,305 shares during the period. Finally, Geode Capital Management LLC grew its stake in Hims & Hers Health by 0.9% during the fourth quarter. Geode Capital Management LLC now owns 4,329,996 shares of the company's stock valued at $104,724,000 after acquiring an additional 40,447 shares in the last quarter. 63.52% of the stock is currently owned by hedge funds and other institutional investors.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.